110 related articles for article (PubMed ID: 2567421)
1. Debrisoquine hydroxylation phenotypes in healthy volunteers.
Llerena A; Cobaleda J; Benítez J
Lancet; 1989 Jun; 1(8651):1398. PubMed ID: 2567421
[No Abstract] [Full Text] [Related]
2. Debrisoquine hydroxylation polymorphism and personality.
Bertilsson L; Alm C; De Las Carreras C; Widen J; Edman G; Schalling D
Lancet; 1989 Mar; 1(8637):555. PubMed ID: 2564084
[No Abstract] [Full Text] [Related]
3. Polymorphism of debrisoquine hydroxylation among Finns and Lapps.
Arvela P; Kirjarinta M; Kirjarinta M; Kärki N; Pelkonen O
Br J Clin Pharmacol; 1988 Nov; 26(5):601-3. PubMed ID: 3207564
[TBL] [Abstract][Full Text] [Related]
4. Debrisoquine hydroxylation phenotyping: do we expect too much?
Mitchell SC; Haley CS
Lancet; 1990 Sep; 336(8716):694. PubMed ID: 1975883
[No Abstract] [Full Text] [Related]
5. Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese.
Yue QY; Bertilsson L; Dahl-Puustinen ML; Säwe J; Sjöqvist F; Johansson I; Ingelman-Sundberg M
Lancet; 1989 Oct; 2(8667):870. PubMed ID: 2571799
[No Abstract] [Full Text] [Related]
6. Diurnal effects on debrisoquine hydroxylation phenotyping.
Lee EJ
Eur J Clin Pharmacol; 1988; 35(4):441-2. PubMed ID: 3197754
[TBL] [Abstract][Full Text] [Related]
7. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications.
Bertilsson L; Mellström B; Sjökvist F; Mårtenson B; Asberg M
Lancet; 1981 Mar; 1(8219):560-1. PubMed ID: 6111662
[No Abstract] [Full Text] [Related]
8. A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians.
Mahgoub A; Idle JR; Smith RL
Xenobiotica; 1979 Jan; 9(1):51-6. PubMed ID: 760321
[TBL] [Abstract][Full Text] [Related]
9. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism.
Küpfer A; Schmid B; Preisig R; Pfaff G
Lancet; 1984 Sep; 2(8401):517-8. PubMed ID: 6147572
[No Abstract] [Full Text] [Related]
10. Debrisoquine phenotype and genotype in Chinese.
Caporaso N; Pickle L
Lancet; 1989 Dec 23-30; 2(8678-8679):1534-5. PubMed ID: 2574814
[No Abstract] [Full Text] [Related]
11. Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.
Davies DS; Kahn GC; Murray S; Brodie MJ; Boobis AR
Br J Clin Pharmacol; 1981 Jan; 11(1):89-91. PubMed ID: 7213514
[No Abstract] [Full Text] [Related]
12. Methoxyphenamine and dextromethorphan as safe probes for debrisoquine hydroxylation polymorphism.
Roy SD; Hawes EM; Hubbard JW; McKay G; Midha KK
Lancet; 1984 Dec; 2(8416):1393. PubMed ID: 6150386
[No Abstract] [Full Text] [Related]
13. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
Alván G; Grind M; Graffner C; Sjöqvist F
Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
[TBL] [Abstract][Full Text] [Related]
14. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.
Brøsen K; Gram LF; Haghfelt T; Bertilsson L
Pharmacol Toxicol; 1987 Apr; 60(4):312-4. PubMed ID: 3588528
[TBL] [Abstract][Full Text] [Related]
15. The metabolism of debrisoquine in man: (1) regioselectivity of hydroxylation and (2) aberrant oxidative metabolism in two sibling patients with carbimazole-induced agranulocytosis.
Ritchie JC; Crothers MJ; Shah RR; Idle JR; Smith RL
Xenobiotica; 1986 May; 16(5):503-9. PubMed ID: 3739370
[TBL] [Abstract][Full Text] [Related]
16. Polymorphic hydroxylation of debrisoquine in Ghanaians [proceedings].
Andoh B; Idle JR; Mahgoub A; Sloan TP; Smith RL; Woolhouse N
Br J Pharmacol; 1979 Jul; 66(3):431P. PubMed ID: 526720
[No Abstract] [Full Text] [Related]
17. High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation.
Alvan G; von Bahr C; Seidemann P; Sjöqvist F
Lancet; 1982 Feb; 1(8267):333. PubMed ID: 6120324
[No Abstract] [Full Text] [Related]
18. Hypotensive response to debrisoquine and hydroxylation phenotype.
Idle JR; Mahgoub A; Lancaster R; Smith RL
Life Sci; 1978 Mar; 22(11):979-83. PubMed ID: 642709
[No Abstract] [Full Text] [Related]
19. Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators.
Spina E; Steiner E; Dumont E; Dahlqvist R
Psychopharmacol Ser; 1989; 7():201-5. PubMed ID: 2687858
[No Abstract] [Full Text] [Related]
20. Low frequency of slow debrisoquine hydroxylation in a native Chinese population.
Lou YC; Ying L; Bertilsson L; Sjöqvist F
Lancet; 1987 Oct; 2(8563):852-3. PubMed ID: 2889047
[No Abstract] [Full Text] [Related]
[Next] [New Search]
